Royal Bank of Canada Downgrades Regeneron Pharmaceuticals to 'Sector Perform'

Regeneron Pharmaceuticals (NASDAQ:REGN) stock has been reaffirmed as 'sector perform' by analysts at Royal Bank Of Canada, who also set a price target of $737.00.

This rating and price objective indicate a potential downside of 2.03% from the company's previous close.

Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for serious medical conditions, including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases, and rare conditions.